Journal News

Decoding microglial language

Arti Dumbrepatil
May 14, 2024

Microglia are resident immune cells of the central nervous system that can be rapidly activated to initiate immune responses. They play an important role in neurodegenerative diseases and neuroinflammation. Neurodegenerative disease-associated microglia, or DAM, mediate neuroinflammatory responses in Alzheimer’s disease by secreting extracellular vesicles. These EVs are lipid-bound vesicles composed of lipids, proteins, metabolites and nucleic acids. Researchers do not yet know how EVs modulate cell-to-cell communication in disease pathogenesis.

Scientists at Emory University used proteomics and transcriptomics to interpret the microglial language and to understand how EVs’ cargo transfers an inflammatory signal to recipient cells, thus exacerbating neuroinflammatory conditions. Their study was published in Molecular & Cellular Proteomics.

The first author, Juliet Santiago, recently graduated from Emory. “I like to compare intercellular communication to UPS or FedEx, where EVs are the packages sent from one cell to another,” she said. “EVs carry messages or signals contained within the package that can impact the recipient. In this case, initiating an inflammatory response in the recipient cell. Microglia-secreted EV cargo has the potential to elicit an inflammatory response and to transmit those signals to other microglia, worsening the inflammatory condition.”

Microglia alter their morphology, molecular profile and function in response to immune activators, exerting different functions in different diseases. Microglia-mediated neuroinflammation is a key pathological component of several neurodegenerative diseases, including Alzheimer’s. These extracellular vesicles released by microglia contribute to how Alzheimer’s propagates and progresses over time.

The microglial activation state determines EVs’ unique molecular profiles. In this study, the research team used size-exclusion chromatography to purify EVs from BV-2, a microglial cell line and obtained their molecular profiles with label-free quantitative mass spectrometry and mRNA and noncoding RNA sequencing methods.

The corresponding author of the paper Srikant Rangaraju, now a professor at Yale University, was a professor at Emory University when this work was published. “We use in vitro models to obtain microglia cells,” he said, “and exposed them to different stimuli to understand what protein and RNA changes are happening in the extracellular vesicles specifically.”

The researchers treated BV2 microglia with lipopolysaccharide, interleukin-10 or transforming growth factor beta, to mimic proinflammatory, anti-inflammatory or homeostatic states, respectively. Their proteomic and transcriptomic analysis showed that lipopolysaccharide treatment profoundly impacted the compositions of microglia-derived EVs. Further, they found that EVs derived from lipopolysaccharide-activated microglia were able to induce proinflammatory transcriptomic changes in resting responder microglia, confirming the ability of microglia-derived EVs to relay inflammatory signals.

 “We found that the state of microglia impacts the profile of the extracellular vesicles they secrete,” Santiago said. “Taking it a step further, we did transcriptomics on the secreted EVs cargo and we were able to quantify the messenger RNAs. The EVs released after inflammation contained an abundant amount of messenger RNA making us realize that maybe these EVs were mediating translation in the recipient cell, deciding the fate of the recipient cell. In short, EVs have the potential to affect the course of disease progression.”
EVs also play a critical role in cancer progression and viral infections. Scientists are working to engineer EVs to deliver drugs because they can cross the blood-brain barrier.
“Engineering EV cargo for drug delivery or small molecule delivery directly at the affected regions like the brain to help bring about anti-inflammatory responses for rehabilitation or treatment would be a game changer,” Santiago said.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Arti Dumbrepatil

Arti Dumbrepatil is a freelance science writer and communicator. With her academic training plus expertise in science communication and writing, she demystifies and transforms complex, jargon-filled science into enjoyable and comprehensible content that resonates with a diverse audience. She is an ASBMB Today volunteer contributor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Scientists find bacterial ‘Achilles’ heel’ to combat antibiotic resistance
Webinar

Scientists find bacterial ‘Achilles’ heel’ to combat antibiotic resistance

March 28, 2025

Alejandro Vila, an ASBMB Breakthroughs speaker, discussed his work on metallo-β-lactamase enzymes and their dependence on zinc.

Host vs. pathogen and the molecular arms race
ASBMB Annual Meeting

Host vs. pathogen and the molecular arms race

March 28, 2025

Learn about the ASBMB 2025 symposium on host–pathogen interactions, to be held Sunday, April 13 at 1:50 p.m.

Richard Silverman to speak at ASBMB 2025
ASBMB Annual Meeting

Richard Silverman to speak at ASBMB 2025

March 27, 2025

Richard Silverman and Melissa Moore are the featured speakers at the ASBMB annual meeting to be held April 12-15 in Chicago.

From the Journals: JBC
Journal News

From the Journals: JBC

March 25, 2025

How cells recover from stress. Cancer cells need cysteine to proliferate. Method to make small membrane proteins. Read about papers on these topics recently published in the Journal of Biological Chemistry.

ASBMB names 2025 JBC/Tabor Award winners
Award

ASBMB names 2025 JBC/Tabor Award winners

March 24, 2025

The six awardees are first authors of outstanding papers published in 2024 in the Journal of Biological Chemistry.

Pan-kinase inhibitor for head and neck cancer enters clinical trials
Journal News

Pan-kinase inhibitor for head and neck cancer enters clinical trials

March 18, 2025

A drug targeting the scaffolding function of multiple related kinases halts tumor progression.